4:53 PM
 | 
Mar 01, 2019
 |  BC Extra  |  Financial News

Genome editing company Precision proposes $100M IPO

With plans to bring an allogeneic CAR T immunotherapy into the clinic, Precision BioSciences Inc. (Durham, N.C.) proposed Friday to raise up to $100 million in an IPO on NASDAQ.

Precision plans to start this half a Phase I/IIa trial of lead program, PBCAR0191, in acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma (NHL). The allogeneic CAR T cell therapy targeting CD19 has Orphan...

Read the full 293 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >